* Disclaimer:  Our products and technologies are currently not available for clinical use. FDA or other regulatory agencies have not evaluated the statements on this website regarding our products and technologies. 

Theragnostic Technologies Receives Small Business Technology Transfer (STTR) Phase I Award in Partnership with Stony Brook University

September 25, 2013

Theragnostic Technologies  has received Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Diabestes and Digestive and Kidney Diseases in collaboration with  Stony Brook University. This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure. 

 

The research will be led by Dr. Balaji Sitharaman in the Department of Biomedical Engineering. Dr Kenneth Shroyer (Department of Pathology) and Dr. William Moore (Department of Radiology) serve as clinical co-PIs in partnership with Scientists at Theragnostic Technologies.

 

 

 

Please reload

Recent Posts
Please reload